ADAR1 is a new target of METTL3 and plays a pro-oncogenic role in glioblastoma by an editing-independent mechanism.


Journal

Genome biology
ISSN: 1474-760X
Titre abrégé: Genome Biol
Pays: England
ID NLM: 100960660

Informations de publication

Date de publication:
28 01 2021
Historique:
received: 27 05 2020
accepted: 14 01 2021
entrez: 29 1 2021
pubmed: 30 1 2021
medline: 15 12 2021
Statut: epublish

Résumé

N Here, we show that METTL3, upregulated in glioblastoma, methylates ADAR1 mRNA and increases its protein level leading to a pro-tumorigenic mechanism connecting METTL3, YTHDF1, and ADAR1. We show that ADAR1 plays a cancer-promoting role independently of its deaminase activity by binding CDK2 mRNA, underlining the importance of ADARs as essential RNA-binding proteins for cell homeostasis as well as cancer progression. Additionally, we show that ADAR1 knockdown is sufficient to strongly inhibit glioblastoma growth in vivo. Hence, our findings underscore METTL3/ADAR1 axis as a novel crucial pathway in cancer progression that connects m6A and A-to-I editing post-transcriptional events.

Sections du résumé

BACKGROUND
N
RESULTS
Here, we show that METTL3, upregulated in glioblastoma, methylates ADAR1 mRNA and increases its protein level leading to a pro-tumorigenic mechanism connecting METTL3, YTHDF1, and ADAR1. We show that ADAR1 plays a cancer-promoting role independently of its deaminase activity by binding CDK2 mRNA, underlining the importance of ADARs as essential RNA-binding proteins for cell homeostasis as well as cancer progression. Additionally, we show that ADAR1 knockdown is sufficient to strongly inhibit glioblastoma growth in vivo.
CONCLUSIONS
Hence, our findings underscore METTL3/ADAR1 axis as a novel crucial pathway in cancer progression that connects m6A and A-to-I editing post-transcriptional events.

Identifiants

pubmed: 33509238
doi: 10.1186/s13059-021-02271-9
pii: 10.1186/s13059-021-02271-9
pmc: PMC7842030
doi:

Substances chimiques

Protein Isoforms 0
RNA, Messenger 0
RNA-Binding Proteins 0
YTHDF1 protein, human 0
Methyltransferases EC 2.1.1.-
METTL3 protein, human EC 2.1.1.62
ADAR protein, human EC 3.5.4.37
Adenosine Deaminase EC 3.5.4.4
Adenosine K72T3FS567

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

51

Références

Annu Rev Biochem. 2010;79:321-49
pubmed: 20192758
Trends Genet. 2019 Dec;35(12):903-913
pubmed: 31648814
Hum Genet. 2017 Sep;136(9):1265-1278
pubmed: 28913566
Cancer Cell Int. 2020 Dec 14;20(1):597
pubmed: 33317545
Nature. 2018 Jun;558(7711):605-609
pubmed: 29925953
Cancer Cell. 2015 Oct 12;28(4):515-528
pubmed: 26439496
Trends Genet. 2016 Dec;32(12):763-773
pubmed: 27793360
Cell Death Dis. 2018 Jul 23;9(8):796
pubmed: 30038300
Nucleic Acids Res. 2017 Jun 2;45(10):6051-6063
pubmed: 28334903
Curr Oncol Rep. 2019 Mar 5;21(4):30
pubmed: 30835007
J Am Chem Soc. 2003 Sep 10;125(36):10867-76
pubmed: 12952466
Front Oncol. 2019 Dec 12;9:1403
pubmed: 31921660
Biochim Biophys Acta Gene Regul Mech. 2019 Mar;1862(3):222-229
pubmed: 30395944
Cancer. 2013 Mar 1;119(5):1004-12
pubmed: 23132729
Nat Med. 2013 Feb;19(2):209-16
pubmed: 23291631
Biochemistry. 2019 Feb 5;58(5):363-378
pubmed: 30557013
Oncogene. 2018 Jan 25;37(4):522-533
pubmed: 28991227
EMBO J. 2009 Oct 21;28(20):3145-56
pubmed: 19713932
Transl Oncol. 2016 Dec;9(6):548-556
pubmed: 27863310
Cell Stem Cell. 2016 Aug 4;19(2):177-191
pubmed: 27292188
Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4621-6
pubmed: 10200312
Genome Biol. 2019 Feb 13;20(1):33
pubmed: 30760294
Nat Protoc. 2013 Jan;8(1):176-89
pubmed: 23288318
Cancer Res. 2019 Apr 1;79(7):1285-1292
pubmed: 30894375
Leukemia. 2017 Dec;31(12):2824-2832
pubmed: 28484266
Mol Ther Nucleic Acids. 2020 Mar 6;19:405-412
pubmed: 31887551
J Biol Chem. 2007 Jun 1;282(22):16054-61
pubmed: 17428802
Nucleic Acids Res. 2018 Feb 28;46(4):2045-2059
pubmed: 29267965
Cancers (Basel). 2020 Mar 10;12(3):
pubmed: 32164324
Mol Cancer. 2019 May 29;18(1):103
pubmed: 31142332
Mol Cell Biol. 2005 Aug;25(16):6956-63
pubmed: 16055709
Biochem Biophys Res Commun. 2008 Dec 5;377(1):170-5
pubmed: 18835380
Nat Commun. 2020 Mar 27;11(1):1580
pubmed: 32221286
Cell. 2012 Jun 22;149(7):1635-46
pubmed: 22608085
Cell Rep. 2017 Mar 14;18(11):2622-2634
pubmed: 28297667
Mol Cell. 2018 Jan 4;69(1):126-135.e6
pubmed: 29304330
Mol Neurobiol. 2019 Mar;56(3):1596-1606
pubmed: 29909453
Nature. 2018 Sep;561(7724):556-560
pubmed: 30232453
Genome Res. 2007 Nov;17(11):1586-95
pubmed: 17908822
Oncogene. 2013 Feb 21;32(8):998-1009
pubmed: 22525274
Mol Cell. 2016 May 5;62(3):335-345
pubmed: 27117702
Nature. 2015 Feb 26;518(7540):560-4
pubmed: 25719671

Auteurs

Valentina Tassinari (V)

Oncohaematology Department, IRCCS Ospedale Pediatrico Bambino Gesu, Viale di San Paolo 15, 00146, Rome, Italy.
Present address: Department of Molecular Medicine, "Sapienza" University of Rome, Rome, Italy.

Valeriana Cesarini (V)

Oncohaematology Department, IRCCS Ospedale Pediatrico Bambino Gesu, Viale di San Paolo 15, 00146, Rome, Italy.
Present address: Department of Biomedical Sciences, Institute of Translational Pharmacology, National Research Council of Italy (CNR), Rome, Italy.

Sara Tomaselli (S)

Oncohaematology Department, IRCCS Ospedale Pediatrico Bambino Gesu, Viale di San Paolo 15, 00146, Rome, Italy.

Zaira Ianniello (Z)

Department of Biology and Biotechnology "Charles Darwin", La Sapienza University of Rome, Rome, Italy.

Domenico Alessandro Silvestris (DA)

Oncohaematology Department, IRCCS Ospedale Pediatrico Bambino Gesu, Viale di San Paolo 15, 00146, Rome, Italy.

Lavinia Ceci Ginistrelli (LC)

Department of Biology and Biotechnology "Charles Darwin", La Sapienza University of Rome, Rome, Italy.

Maurizio Martini (M)

Department of Women's, Children's and Public Health Studies, Fondazione Policlinico Universitario "A. Gemelli", IRCCS, Largo A. Gemelli 8, 00168, Rome, Italy.
Department of Health Science and Public Health, Institute of Pathology, Largo F. vito 1, 00168, Rome, Italy.

Biagio De Angelis (B)

Oncohaematology Department, IRCCS Ospedale Pediatrico Bambino Gesu, Viale di San Paolo 15, 00146, Rome, Italy.

Gabriele De Luca (G)

Department of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161, Rome, Italy.

Lucia Ricci Vitiani (LR)

Department of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161, Rome, Italy.

Alessandro Fatica (A)

Department of Biology and Biotechnology "Charles Darwin", La Sapienza University of Rome, Rome, Italy.

Franco Locatelli (F)

Oncohaematology Department, IRCCS Ospedale Pediatrico Bambino Gesu, Viale di San Paolo 15, 00146, Rome, Italy.
Department of Pediatrics, La Sapienza University of Rome, Rome, Italy.

Angela Gallo (A)

Oncohaematology Department, IRCCS Ospedale Pediatrico Bambino Gesu, Viale di San Paolo 15, 00146, Rome, Italy. angela.gallo@opbg.net.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH